参麦针剂协同腹腔化疗治疗进展期大肠癌的临床观察

《参麦针剂协同腹腔化疗治疗进展期大肠癌的临床观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、参麦针剂协同腹腔化疗治疗进展期大肠癌的临床观察作者：朱伟嵘，郑岚，郭元彪，袁建明，沈小珩【关键词】参麦针剂［摘要］目的：观察参麦针剂（ShenmaiInjection,SMI）协同腹腔化疗（intraperitonealchemotherapy,IPC）治疗进展期大肠癌根治术后患者的疗效。方法：进展期大肠癌根治术后行腹腔化疗患者58例，分成IPC组（22例）和SMI＋IPC组（36例）。IPC组行单纯腹腔化疗（5氟尿嘧啶联合顺铂）；SMI+IPC组采用参麦针剂协同腹腔化疗治疗。每4周为1个疗程，共4～6个疗程。近期疗效观察临床症状

2、、生存质量，治疗前后血白细胞计数、肝肾功能、自然杀伤（naturalkiller,NK）细胞活性、T淋巴细胞亚群中T辅助与T抑制细胞比值（CD4/CD8）；远期疗效观察无瘤生存率。结果：SMI＋IPC组近期总有效率为83.33%，IPC组为63.64%，两组比较有统计学意义（P＜0.05)；SMI＋IPC能改善临床症状，提高生存质量，维持血白细胞的稳定，提高NK细胞活性和CD4/CD8的比值，与IPC组比较，均有统计学意义（P＜0.05或P＜0.01)。SMI＋IPC可提高患者5年无瘤生存率。结论：参麦针剂协同腹腔化疗是治疗进展期

3、大肠癌根治术后患者的有效方法。12　　［关键词］参麦针剂;腹腔化疗;大肠癌;临床研究　　ClinicalresearchofintraperitonealchemotherapyplusShenmaiInjectionintreatingadvancedcolorectalcancer　　ABSTRACTObjective:Tostudytheeffectsofintraperitonealchemotherapy(IPC)plusShenmaiInjection(SMI)intreatingadvancedcolorectalc

4、ancerfollowingradicalresections.Methods:FiftyeightcasesofcolorectalcancerinstageB2andCfollowingradicalresectionsweredividedintotwogroups:SMI＋IPCgroup(36cases)andIPCgroup(22cases).IntheSMI＋IPCgroup,IPC(5fluorouracilcombinedwithcisplatin)plusSMIwasadministered,whileinth

5、eIPCgroup,onlyIPCwasadministered.Clinicalsymptoms,qualityoflife(Karnofskyscore),whitebloodcellcounts,naturalkillercellsandCD4/CD8wereobserved,anddiseasefreesurvival(DFS)ratewasalsoevaluated.Results:Thetotalshorttermresponseratewas83.33%intheSMI＋IPCgroup,significantlyh

6、igherthan63.64%intheIPCgroup(P<0.05).Thedataofclinicalsymptoms,qualityoflife,whitebloodcellcounts,naturalkillercellsandCD4/CD8intheSMI＋IPCgroupwerealsosignificantlyimprovedascomparedwiththoseintheIPCgroup12(P＜0.05orP＜0.01).IntheSMI＋IPCgroup,1,3and5yearDFSrateswere9

7、1.7%(33/36),77.8%(28/36)and72.2%(26/36)respectively,andthoseintheIPCgroupwere90.9%(20/22),72.7%(16/22)and45.5%(10/22)respectively.The5yearDFSratewassignificantlyimprovedintheSMI＋IPCgroupascomparedwiththatintheIPCgroup(P<0.05),whilethe1yearand3yearDFSrateshadnosigni

8、ficantdifferencebetweenthesetwogroups.Conclusion:IPCplusSMIiseffectiveintreatingpostoperativepatientswithadvancedcolorectalc